# Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

> **NCT04648254** · PHASE1 · COMPLETED · sponsor: **Qurient Co., Ltd.** · enrollment: 51 (actual)

## Conditions studied

- Solid Tumor
- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Q702

## Key facts

- **NCT ID:** NCT04648254
- **Lead sponsor:** Qurient Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2025-12-23
- **Final completion:** 2025-12-23
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04648254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04648254, "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04648254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*